JOGO HEALTH to present evidence of digital therapeutics at ANZSCoS Annual Scientific Meeting

JOGOHEALTH Inc., a privately held digital therapeutics company focused on the development and commercialization of treatments for neuromuscular (NM) conditions such as stroke, spinal cord injury, cerebral palsy and urinary incontinence today announced that it will present evidence and performance of its lead investigational product JOGO, at the 2019 Australian & New Zealand Spinal Cord Society (ANZSCoS) Annual Scientific Meeting held at Pullman Melbourne Albert Park in Melbourne, Australia from 21 – 23 August 2019.

Read more

Quest Diagnostics Now Participating in NCI-MATCH Precision Medicine Clinical Trial

As the leader in Advanced Diagnostics, including Next Generation Sequencing (NGS), Quest joins a select group of commercial and academic laboratories to meet the rigorous requirements for participation in this clinical trial.
Both the Quest Med Fusion 50SEQ cancer panel and IBM Watson Genomics from Quest Diagnostics service fulfill the trial’s criteria for accuracy and reliability in tumor profiling.

Read more